MOLN

MOLN

Molecular Partners AG ADR

Molecular Partners AG develops designed ankyrin repeat protein therapeutics for oncology, focusing on treatments for solid tumors, acute myeloid leukemia, and ovarian cancer. Its pipeline includes various candidates in Phase 1 and Phase 2 trials.

⚕️ Healthcare NASDAQ Listed 2021 CHF
$1,000 invested 5 years ago $215today

Score Overview

1 Year
Score
Net Growth-16.88%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score3.0
Net Growth-12.97%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-12.97%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency

See the full market ranking →

Molecular Partners AG ADR fundamental performance

Between 2021 and 2025, revenue declined from CHF 9M to CHF 0.00 and net income went from -CHF 63M to -CHF 61M. Revenue increased in 20% of the years measured; net income in 40%.

Molecular Partners AG ADR currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-11
$ 4.13
1 Year2025-08-12
$ 3.4719.02%
5 Years2021-08-12
$ 19.20-78.49%
All Time2021-06-16
$ 19.65-78.98%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026CHF 0.00-CHF 72MCHF 78M
2025CHF 0.00-CHF 61MCHF 93M
2024CHF 4M-CHF 54MCHF 149M
2023CHF 7M-CHF 61MCHF 186M
2022CHF 189MCHF 117MCHF 249M
IPO2021CHF 9M-CHF 63MCHF 132M

Explore beyond MOLN

You're looking at Molecular Partners AG ADR. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies